Dr. Guy Chamberland, Chief Executive Officer of Tetra Bio-Pharma will give an overview of the Company. He will present the company's pipeline, especially its lead program - ARDS-003, as well as the recent acquisition of the Canadian Distribution Rights for Dronabinol Soft Gel Capsules and aim to establish a commercial presence in Canada. Dr. Chamberland will then respond to Investors questions.
Tetra Bio-Pharma - Town Hall Agenda
CEO Presentation - 10 to 15 minutes
Follow-up Q&A - 10 to 15 minutes
The presentation will be webcast live. You can register to the Virtual Town Hall with the following link:
REGISTER
https://zoom.us/webinar/register/WN_aEQqsHkiTNqI7z8pfQBnZA
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF), is a biopharmaceutical leader in cannabinoid-based drug discovery and development with FDA and Health Canada approved clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com